CAMRIS International (CAMRIS), a Bethesda-based research firm, was recently awarded the Malaria Antigen Discovery (MAD) contract which will provide support for the Naval Medical Research Center’s (NMRC’s) malaria research program. CAMRIS also was the holder of the previous MAD contract. The goal of the contract is to develop a vaccine that kills malaria parasites. Patent prosecution in this innovative technology is ongoing.
The MAD contract continues our efforts to combat malaria. In addition to working with NMRC to develop a malaria vaccine, CAMRIS currently is developing and implementing research products and supporting controlled human malaria infection (CHMI) clinical trials for the Walter Reed Army Institute of Research. Furthermore, CAMRIS previously conducted malaria indicator surveys under the third phase of the Monitoring and Evaluation to Assess and Use Results (MEASURE) Demographic Health Surveys (DHS) project for the U.S. Agency for International Development (USAID), and conducted research on the epidemiology, ecology, and social and economic impacts of malaria under the Field Research in Infectious and Emerging Diseases (FRIED) program for the Naval Medical Research Unit 6 Perú (NAMRU-6).
We are honored to continue our work undertaking research studies and providing expertise in support of ongoing pre-clinical development of a malaria vaccine for NMRC, and we look forward to strengthening our partnership with the agency.